Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pathological complete response (pCR) in
participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant
treatment.